Curcumin Supplementation in Cervical Cancer

Recruiting now · Not applicable

Conditions studied: Locally Advanced Cervical Cancer

In brief

Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are: * Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation? Participants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation: 1. 1 g of curcumin 2. 1 g of curcumin + piperine 3. 3 g of curcumin 4. 3 g of curcumin + piperine 5. 6 g of curcumin 6. 6 g of curcumin + piperine

Key facts

Study ID

NCT06080841

Run by

National Institute of Cancerología

People needed

30

Starts

2023-04-19

Expected to finish

2026-03-01

Last updated by the study team

2025-05-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Understanding the nature of the study and giving a written consent report.
• Women > 18 years old.
• ECOG performance status: 0-2.
• Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests.
• Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma.
• Classified with clinical stage IB3-IVA (FIGO 2018).
• Candidates to receive concomitant QT-RT followed by BT.
• With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria.
• Patients without prior treatment based on QT-RT.
• Hemoglobin ≥ 10 g/dL.
• Leukocytes ≥ 4000/mm3.
• Platelets ≥ 100,000/mm3.
• Adequate liver function.

You may not qualify if…

• Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.
• Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT.
• Patients receiving concomitant treatment with an experimental drug.
• Patients with vesicovaginal or vesicorectal fistula are diagnosed.
• Patients with previous or concomitant malignancy except non-melanoma skin carcinoma.

Where it is running

• Instituto Nacional de Cancerología — Mexico City, Mexico City, Mexico (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.